Financial Data and Key Metrics Changes - Jazz Pharmaceuticals reported record total revenue of $4.3 billion for 2025, reflecting a 5% growth over 2024, with fourth quarter revenue of $1.2 billion, representing a 10% year-over-year growth [6][31] - Non-GAAP adjusted net income for 2025 was approximately $522 million, with non-GAAP adjusted EPS of $8.38 [31] - The company expects total revenue for 2026 to be in the range of $4.25 billion to $4.50 billion, equating to a growth of about 2.5% at the midpoint compared to 2025 [32] Business Line Data and Key Metrics Changes - The rare sleep therapeutic area generated over $2 billion in total revenue in 2025, with XYWAV revenue growing 12% to approximately $1.7 billion for the year [12][31] - Epidiolex achieved blockbuster status with $1.1 billion in revenue, up 9% year-over-year, while Zepzelca generated $307 million in revenue in 2025 [16][21] - Modeyso, launched in August 2025, generated $48 million in revenue by year-end, indicating strong early performance [19] Market Data and Key Metrics Changes - XYWAV remains the number one branded treatment for narcolepsy and the only FDA-approved treatment for idiopathic hypersomnia (IH), with a 34% increase in net active IH patients [14][15] - The competitive landscape for sleep medications is evolving, with two generic versions of high-sodium Xyrem entering the market, expected to negatively impact revenues [15][32] - The company anticipates a modest decrease in rare sleep revenue for 2026, primarily driven by Xyrem and Hikma Pharmaceuticals revenue [32] Company Strategy and Development Direction - Jazz Pharmaceuticals is sharpening its strategic focus on rare diseases, aiming to strengthen current franchises and expand into new areas [8][39] - The company plans to leverage its proven capabilities in corporate development to continue building a more valuable company, particularly in rare diseases [9][39] - Future pipeline advancements and new business development transactions are expected to align with the company's rare disease focus [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and operational excellence, highlighting the potential for significant future growth [5][39] - The company is focused on maximizing the potential of its oncology portfolio, particularly with zanidatamab and its upcoming launch in GEA [10][24] - Management acknowledged the evolving competitive landscape in the sleep market but emphasized the unique value proposition of XYWAV as a low-sodium option [68][75] Other Important Information - The company resolved nearly all major litigation, including settling outstanding ANDA litigation for Epidiolex, which extends its runway into the late 2030s [7][8] - Jazz Pharmaceuticals generated approximately $1.4 billion of cash from operations for the full year 2025, ending the year with $2.4 billion in cash and investments [38] Q&A Session Summary Question: Guidance around XYWAV for 2026 - Management indicated that XYWAV is well-positioned with strong patient adds and unique safety benefits, but acknowledged potential competitive pressures from generics in the second half of 2026 [41][44] Question: Hikma royalty rate and AG volume impact - Management confirmed a modest step down in the Hikma royalty rate for 2026 but emphasized that significant economics will still flow to Jazz [50][51] Question: JZP047 background and development - Management clarified that JZP047 is a novel chemical entity developed in-house, focusing on absence epilepsy, with strong preclinical data supporting its development [54][55] Question: HER2 breast cancer population and potential uptake - Management highlighted the opportunity for zanidatamab in the HER2-positive breast cancer market, estimating around 150,000 patients in the served markets [57][58] Question: XYWAV competitive pressure in the second half - Management expects minimal impact on XYWAV in the first half of 2026 but anticipates increasing competitive dynamics in the second half due to generics and new agents [66][68] Question: Payer contracts and potential negotiations - Management acknowledged the possibility of payers wanting to renegotiate contracts but emphasized the strong commitment from healthcare providers to ensure access to XYWAV [71][74] Question: Future strategy for the sleep-wake franchise - Management stated that they are investing in the growth of all current franchises, including sleep, and are open to opportunities for licensing and M&A to augment growth [85][88]